First-in Human Assessment of the UroActive® Electronic Artificial Urinary Sphincter for Treating Male Stress Urinary Incontinence (SUI) - Beyond the Abstract
In this prospective, multicenter pilot study, Mozer and colleagues report the one-year outcomes of six men with severe post-prostatectomy stress urinary incontinence treated with the UroActive® system. All patients underwent successful implantation and activation, with no revisions, explantations, or device infections during 12 months of follow-up. Continence outcomes were encouraging: median pad use decreased from 3.7 pads/day at baseline to 1.0 pad/day at one year, and all patients achieved at least a 50% reduction in pad weight, with five of six reaching a ≥75% reduction. Patient-reported quality-of-life measures improved substantially across all validated instruments, and satisfaction scores remained uniformly high.
Beyond these favorable early efficacy and safety signals, the true novelty of this device lies in its technological design. Unlike the traditional AMS 800 hydraulic systems, the UroActive® incorporates an electronically controlled pump and reservoir, programmable pressure settings, nocturnal pressure modulation, and remote patient control. The ability to individualize urethral occlusive pressure over time and reduce pressure during periods of inactivity offers a potential strategy to mitigate urethral atrophy and erosion, compared with the current AMS 800. In addition, data logging and clinician programming introduce a new paradigm of personalized continence management.
Several important limitations deserve emphasis. This was a small, highly selected cohort, without prior radiotherapy or previous AUS implantation, and follow-up remains limited. Device deficiencies were confined to the patient's remote control and did not require surgical intervention, but long-term mechanical durability and battery longevity will ultimately determine clinical adoption. Broader clinical experience will be essential before defining the role of electronic sphincters alongside established systems.
Nonetheless, this first-in-human experience marks the first major technological evolution in artificial urinary sphincter design since the introduction of the AMS 800 in the early 1970s. If longer-term studies confirm durability, safety, and reduced revision rates, electronic sphincters may significantly expand treatment options for patients with limited dexterity and those at higher risk for urethral complications. This work represents an important milestone in the modernization of male incontinence surgery and a promising glimpse into the future of next-generation continence devices.
Written by: Daniel S. Elliott, MD, Professor of Urology, Department of Urology, Mayo Clinic, Rochester, MN
Read the Abstract